

AACR Virtual Meeting
Precision Medicine Strategies to Improve Therapy of DLBCL
September 30 – October 1, 2021

Conference Cochairs
Louis M. Staudt, National Cancer Institute, Bethesda, MD
Ranjana H. Advani, Stanford Cancer Institute, Stanford, CA
Georg Lenz, University of Münster, Münster, Germany
Wyndham H. Wilson, National Cancer Institute, Bethesda, MD

September 30, 2021

Session 1: Where Are We Now with DLBCL Therapy?

Current landscape of frontline DLBCL therapy

Ranjana H. Advani, Stanford Cancer Institute, Stanford, CA

Clinical trials in DLBCL: Ideal design meets clinical reality

Grzegorz S. Nowakowski, Mayo Clinic College of Medicine and Science, Rochester, MN

Panel Discussion

Moderator

Sonali M. Smith, University of Chicago, Chicago, IL

Panelists

Ranjana H. Advani

Grzegorz S. Nowakowski

Jeremy S. Abramson, Massachusetts General Hospital, Boston, MA

Brad S. Kahl, Washington University in St. Louis, St. Louis, MO

Judith Trotman, University of Sydney, Sydney, NSW, Australia

Wyndham H. Wilson, National Cancer Institute, Bethesda, MD

Session 2: DLBCL Heterogeneity: Beyond Cell of Origin

The use of DLBCL genetic subtypes to predict response to targeted therapies

Louis M. Staudt, National Cancer Institute, Bethesda, MA

Heterogeneity in tumor phenotype and microenvironment of DLBCL

Ash A. Alizadeh, Stanford University, Stanford, CA

Panel Discussion

Moderator

Ari M. Melnick, Weill Cornell Medical College, New York, NY

Panelists

Ash A. Alizadeh

Louis M. Staudt

Daniel Hodson, University of Cambridge, Cambridge, United Kingdom

Georg Lenz, University of Münster, Münster, Germany

David W. Scott, BC Cancer, Vancouver, BC, Canada

Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA

October 1, 2021

Session 3: Opportunities for Targeted Therapies and Immunotherapies

Specific agents that primarily target the malignant cell

Georg Lenz, University of Münster, Münster, Germany

Naked and armed antibodies in DLBCL

Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, NY

Activating the anti-tumor immune response using immune checkpoint blockade and bi-specific antibodies

Stephen M. Ansell, Mayo Clinic College of Medicine and Science, Rochester, MN

Panel Discussion

Moderator

Louis M. Staudt, National Cancer Institute, Bethesda, MA

Panelists

Stephen M. Ansell

Georg Lenz

Gilles Salles

Martin Hutchings, Copenhagen University Hospital, Copenhagen, Denmark

Marcela V. Maus, Massachusetts General Hospital, Boston, MA

Jason Westin, The University of Texas MD Anderson Cancer Center, Houston, TX

Session 4: Trial Designs of the Future: Challenges and Opportunities

Key issues in DLBCL trial design - who is getting left behind?

Thomas E. Witzig, Mayo Clinic, Rochester, MN

Novel trial designs in diffuse large B-cell lymphoma

Mark Roschewski, National Cancer Institute, Bethesda, MD

Leveraging ctDNA for adapted trials in DLBCL

David M. Kurtz, Stanford University, Stanford, CA

Panel Discussion

Moderator

Wyndham H. Wilson, National Cancer Institute, Bethesda, MA

Panelists

David M. Kurtz

Mark Roschewski

Thomas E. Witzig

Sandra J. Horning, Stanford University School of Medicine, Stanford, CA

Laurie Sehn, BC Cancer, Vancouver, BC, Canada

Louis M. Staudt, National Cancer Institute, Bethesda, MA

Meeting Summary and Closing Remarks

Louis M. Staudt